JP2016508995A5 - - Google Patents

Download PDF

Info

Publication number
JP2016508995A5
JP2016508995A5 JP2015554038A JP2015554038A JP2016508995A5 JP 2016508995 A5 JP2016508995 A5 JP 2016508995A5 JP 2015554038 A JP2015554038 A JP 2015554038A JP 2015554038 A JP2015554038 A JP 2015554038A JP 2016508995 A5 JP2016508995 A5 JP 2016508995A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
formula
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015554038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2014/071205 external-priority patent/WO2014114248A1/en
Publication of JP2016508995A publication Critical patent/JP2016508995A/ja
Publication of JP2016508995A5 publication Critical patent/JP2016508995A5/ja
Pending legal-status Critical Current

Links

JP2015554038A 2013-01-25 2014-01-23 化合物 Pending JP2016508995A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013070970 2013-01-25
CNPCT/CN2013/070970 2013-01-25
PCT/CN2014/071205 WO2014114248A1 (en) 2013-01-25 2014-01-23 Compounds

Publications (2)

Publication Number Publication Date
JP2016508995A JP2016508995A (ja) 2016-03-24
JP2016508995A5 true JP2016508995A5 (enExample) 2016-12-28

Family

ID=51226938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015554038A Pending JP2016508995A (ja) 2013-01-25 2014-01-23 化合物

Country Status (10)

Country Link
US (1) US9296755B2 (enExample)
EP (1) EP2948457A4 (enExample)
JP (1) JP2016508995A (enExample)
KR (1) KR20150111356A (enExample)
CN (1) CN105008365B (enExample)
AU (1) AU2014210259B2 (enExample)
BR (1) BR112015017768A2 (enExample)
CA (1) CA2899124A1 (enExample)
RU (1) RU2015135806A (enExample)
WO (1) WO2014114248A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
IL292668A (en) 2019-11-09 2022-07-01 Shanghai Simr Biotechnology Co Ltd A tricyclic derivative of dihydroimidazopyrimidone, its preparation method, pharmaceutical preparation and its use
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
HUT77089A (hu) 1994-12-22 1998-03-02 Smithkline Beecham Plc. Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
NZ311684A (en) 1995-07-01 2000-04-28 Smithkline Beecham Plc Azetidinone derivatives, preparation, and use for treating atherosclerosis
WO1997012963A2 (en) 1995-09-29 1997-04-10 Smithkline Beecham Plc A paf-acetylhydrolase and use in therapy
JP2000502079A (ja) 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
WO1997021676A1 (en) 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
JP2000509049A (ja) 1996-04-26 2000-07-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療用アゼチジノン誘導体
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
DE69816471T2 (de) 1997-11-06 2004-05-27 Smithkline Beecham P.L.C., Brentford Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
JP2002523402A (ja) 1998-08-21 2002-07-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療用ピリミジノン
HUP0201122A3 (en) 1999-05-01 2003-11-28 Smithkline Beecham Plc Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
HU229479B1 (en) 2000-02-16 2014-01-28 Glaxo Group Ltd Pyrimidine-4-one derivatives
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1558606A4 (en) 2002-10-02 2008-05-07 Bristol Myers Squibb Co DIAMINOALKYL CONTAINING LACTAM, BETA AMINO ACIDS, ALPHA AMINO ACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
EP1558585B1 (en) 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080103156A1 (en) 2006-10-13 2008-05-01 Leach Colin A Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
BRPI0810336A2 (pt) 2007-05-11 2019-03-19 The Trustees Of The University Of Pennsylvania "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
US20080279846A1 (en) * 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
JP5848712B2 (ja) 2009-12-11 2016-01-27 ノノ インコーポレイテッド 虚血性疾患および他の疾患を治療するための薬剤および方法
AU2011340690C1 (en) * 2010-12-06 2016-03-10 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp - PLA2
JP2013545792A (ja) 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
US9273054B2 (en) 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors

Similar Documents

Publication Publication Date Title
JP2017504635A5 (enExample)
JP2019524883A5 (enExample)
JP2014511891A5 (enExample)
JP2016531126A5 (enExample)
JP2014511892A5 (enExample)
JP2017071634A5 (enExample)
RU2016134751A (ru) Соединения
JP2016514159A5 (enExample)
JP2014521688A5 (enExample)
JP2019518766A5 (enExample)
JP2014503574A5 (enExample)
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2016530259A5 (enExample)
JP2015509535A5 (enExample)
JP2017509586A5 (enExample)
JP2016505614A5 (enExample)
JP2016515561A5 (enExample)
JP2016518328A5 (enExample)
JP2015508103A5 (enExample)
JP2014501766A5 (enExample)
JP2016506961A5 (enExample)
JP2013542261A5 (enExample)
JP2015522650A5 (enExample)
JP2017514910A5 (enExample)
JP2016512547A5 (enExample)